Literature DB >> 16917489

Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction.

Lydie Trautmann1, Loury Janbazian, Nicolas Chomont, Elias A Said, Sylvain Gimmig, Benoit Bessette, Mohamed-Rachid Boulassel, Eric Delwart, Homero Sepulveda, Robert S Balderas, Jean-Pierre Routy, Elias K Haddad, Rafick-Pierre Sekaly.   

Abstract

The engagement of programmed death 1 (PD-1) to its ligands, PD-L1 and PD-L2, inhibits proliferation and cytokine production mediated by antibodies to CD3 (refs. 5,6,7). Blocking the PD-1-PD-L1 pathway in mice chronically infected with lymphocytic choriomeningitis virus restores the capacity of exhausted CD8(+) T cells to undergo proliferation, cytokine production and cytotoxic activity and, consequently, results in reduced viral load. During chronic HIV infection, HIV-specific CD8(+) T cells are functionally impaired, showing a reduced capacity to produce cytokines and effector molecules as well as an impaired capacity to proliferate. Here, we found that PD-1 was upregulated on HIV-specific CD8(+) T cells; PD-1 expression levels were significantly correlated both with viral load and with the reduced capacity for cytokine production and proliferation of HIV-specific CD8(+) T cells. Notably, cytomegalovirus (CMV)-specific CD8(+) T cells from the same donors did not upregulate PD-1 and maintained the production of high levels of cytokines. Blocking PD-1 engagement to its ligand (PD-L1) enhanced the capacity of HIV-specific CD8(+) T cells to survive and proliferate and led to an increased production of cytokines and cytotoxic molecules in response to cognate antigen. The accumulation of HIV-specific dysfunctional CD8(+) T cells in the infected host could prevent the renewal of a functionally competent HIV-specific CD8(+) repertoire.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16917489     DOI: 10.1038/nm1482

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  739 in total

1.  Simultaneous blockade of multiple immune system inhibitory checkpoints enhances antitumor activity mediated by interleukin-15 in a murine metastatic colon carcinoma model.

Authors:  Ping Yu; Jason C Steel; Meili Zhang; John C Morris; Thomas A Waldmann
Journal:  Clin Cancer Res       Date:  2010-10-05       Impact factor: 12.531

2.  Development of spontaneous anergy in invariant natural killer T cells in a mouse model of dyslipidemia.

Authors:  Nicole A Braun; Yanice V Mendez-Fernandez; Roman Covarrubias; Steven A Porcelli; Paul B Savage; Hideo Yagita; Luc Van Kaer; Amy S Major
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-06-10       Impact factor: 8.311

Review 3.  Plasticity in programming of effector and memory CD8 T-cell formation.

Authors:  Ramon Arens; Stephen P Schoenberger
Journal:  Immunol Rev       Date:  2010-05       Impact factor: 12.988

4.  T cell and APC dynamics in situ control the outcome of vaccination.

Authors:  Kamal M Khanna; David A Blair; Anthony T Vella; Stephen J McSorley; Sandip K Datta; Leo Lefrançois
Journal:  J Immunol       Date:  2010-06-07       Impact factor: 5.422

5.  PD-1 inhibits T cell proliferation by upregulating p27 and p15 and suppressing Cdc25A.

Authors:  Nikolaos Patsoukis; Duygu Sari; Vassiliki A Boussiotis
Journal:  Cell Cycle       Date:  2012-10-03       Impact factor: 4.534

6.  Distinct profiles of cytotoxic granules in memory CD8 T cells correlate with function, differentiation stage, and antigen exposure.

Authors:  Alexandre Harari; Felicitas Bellutti Enders; Cristina Cellerai; Pierre-Alexandre Bart; Giuseppe Pantaleo
Journal:  J Virol       Date:  2009-01-28       Impact factor: 5.103

7.  PD-1/PD-L blockade prevents anergy induction and enhances the anti-tumor activities of glycolipid-activated invariant NKT cells.

Authors:  Vrajesh V Parekh; Saif Lalani; Sungjune Kim; Ramesh Halder; Miyuki Azuma; Hideo Yagita; Vipin Kumar; Lan Wu; Luc Van Kaer
Journal:  J Immunol       Date:  2009-03-01       Impact factor: 5.422

8.  CTLA-4 and PD-1 dual blockade induces SIV reactivation without control of rebound after antiretroviral therapy interruption.

Authors:  Justin Harper; Shari Gordon; Chi Ngai Chan; Hong Wang; Emily Lindemuth; Cristin Galardi; Shane D Falcinelli; Samuel L M Raines; Jenna L Read; Kevin Nguyen; Colleen S McGary; Michael Nekorchuk; Kathleen Busman-Sahay; James Schawalder; Colin King; Maria Pino; Luca Micci; Barbara Cervasi; Sherrie Jean; Andrew Sanderson; Brian Johns; A Alicia Koblansky; Heather Amrine-Madsen; Jeffrey Lifson; David M Margolis; Guido Silvestri; Katharine J Bar; David Favre; Jacob D Estes; Mirko Paiardini
Journal:  Nat Med       Date:  2020-03-16       Impact factor: 53.440

9.  Programmed death-1+ T cells inhibit effector T cells at the pathological site of miliary tuberculosis.

Authors:  A Singh; A Mohan; A B Dey; D K Mitra
Journal:  Clin Exp Immunol       Date:  2016-11-24       Impact factor: 4.330

10.  HIV-Specific T Cells Generated from Naive T Cells Suppress HIV In Vitro and Recognize Wide Epitope Breadths.

Authors:  Shabnum Patel; Elizabeth Chorvinsky; Shuroug Albihani; Conrad Russell Cruz; R Brad Jones; Elizabeth J Shpall; David M Margolis; Richard F Ambinder; Catherine M Bollard
Journal:  Mol Ther       Date:  2018-04-12       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.